Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Autoimmune diseases, such as multiple sclerosis and type-1 diabetes, are the outcomes of a failure of immune tolerance. Immune tolerance is sustained through interplays between two inter-dependent clusters of immune activities: immune stimulation and immune regulation. The mechanisms of immune regul...
Main Authors: | Yujia Zhai, Reza Moosavi, Mingnan Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.645699/full |
Similar Items
-
Immune Checkpoints as Therapeutic Targets in Autoimmunity
by: Christopher Paluch, et al.
Published: (2018-10-01) -
Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis
by: Albert J. Czaja
Published: (2019-05-01) -
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies
by: Sarah Soussan, et al.
Published: (2024-01-01) -
Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
by: Vafa Meftahpour, et al.
Published: (2022-01-01) -
Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma
by: Yi-Ru Pan, et al.
Published: (2022-10-01)